<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

# 510(k) Substantial Equivalence Determination Decision Summary

A. 510(k) number: K121044

ustanl ualec r he il® Gru et  A plat used for the qualitative detection of Streptococcus agalactiae.

C. Measurand: Segment of the Streptococcus agalactiae genome

QualitativiiagossLoo-ediatsohermalDA plicatin AMPoy

E. Applicant: Meridian Bioscience, Inc.

F. Propriety and Established Names: illumigene® Group B Streptococcus (GBS) DNA Amplification Assay

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code                          </td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>NJR, Nucleic acid amplification assay system,Streptococcus spp., serological reagents</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR $ 866.3740</td><td rowspan=1 colspan=1>Microbiology (83)</td></tr></table>

# H. Intended Use:

1.Intended use(s):

The l Gru  rts ssy peone-0,   qualitatn gretnaaccuuaiagil specmens fromanteparum womeEnriche cultures are obtained by -4 hour incubation vaginal/al swab specimens in selective broth medium, Lim Broth, TransVag Broth or Carrot Broth.

The illumigene GBS assay utilizes loop-ediated isothermal DNA amplification (LAMP) technology todetect Sreptococcus agalactie by targetig a segment of theStreptococcus agalactie enome.Results from the illigene B assyne used s n id inestablishing the  colonization statu antepartum women. This assay does not diagnose or monitor treatment for GBS infections. The illumigene GBS assay does not bu for penicillin-allergic women.

<table><tr><td rowspan="2">Meridian 3</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number.</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

iGr  o  y t device is not intended for point-of-care use.

# 2. Indication(s) for use:

T il Grureptou s pehep-0,s  qalitaiv agosorheetenetcalactrecultutaiagialr specimens from antepartum womennriched cultures are obtained by 1-4 hour incubation  vaginal/ral swab specimens in selective broth medium, Lim Broth, TransVag Broth or Carrot Broth.

The illumigene GBS assay utilizes loop-mediated isothermal DNA amplification (LAMP) technology to detect Sreptococcus agalactie by targeting a segment of the Streptococcus agalactie genome.Results rom the illigene  assy n be used as nid nestablishing the  colonization statu antepartum women. This assay does not diagnose or monitor treatment for GBS infections. The illumigene GBS assay does not l ula bl for penicillin-allergic women.

ilGrou  t oruosp c a oa etT device is not intended for point-of-care use.

# 3. Special Conditions for use statement(s):

For Prescription Use Only The device is not intended for point-of-care use

4. Special instrument requirements:

illumipro $1 0 ^ { m }$ Automated Isothermal Amplification and Detection System

# I. Device Description:

Te ille Moluar gos stcie ille® Groretcs ) AmplifitinTest , the illuie Grou B treptos GB)Exteral Conrol t and the illo ${ \bf \nabla } \cdot { \bf \nabla } \mathcal { 1 } 0 ^ { m }$ Automated Isothermal Amplification and Detection System.

TeG r ) liatasil o-a LAMP) technology to detect the presence of Streptococcus agalactie in enriched cultures obtained from vaginal/rectal swab specimens taken from antepartum women. Each illumigene GBS assay is completed using illeConto ReaillRean Bufille Te Devic n nilleHe Treaent Tube Samples redilute with theiigeContolReagent, rget DA ismadeavailable or aicatelebcat the illumigene GBS Test Device.

The illumipro-10 heats each lumigene GBS Test Device containing prepared samples and Control Reagent, fliplataecl nce heagalacti s mplid an magnesi pyrohosphat  forme Magnes pyrophoshat Negative based on the detected change in light transmission.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td><td rowspan="2"></td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td><td></td></tr></table>

The ille Grou Strepts  Exteal Control  cnsst a osiv onRagent n a Negative Control Reagent. External Control reagents are provided to aid the user in detection of reagent etinveventitine ch errs.The llien Group  Streptoccs xternal Control Ki  required or routi Quality Conol

# J. Substantial Equivalence Information:

Predicate device name(s): illumigene Group B Streptococcus (GBS) Assay

2. Predicate 510(k) numbers: K112125

3.Comparison with predicates:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DEVICES            illumigene® GBSK121044   -</td><td colspan="1" rowspan="1">PREDICATEillumigene® GBSK112125</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">DNA Amplification Assay</td><td colspan="1" rowspan="1">Same.</td></tr><tr><td colspan="1" rowspan="1">DNA AmplificationTechnology</td><td colspan="1" rowspan="1">Loop-Mediated Isothermal Amplification (LAMP)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Target SequencesDetected</td><td colspan="1" rowspan="1">213 base pair (bp) sequence residing in the 593-805bp region of S. agalactiae genome Segment 3</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen Types</td><td colspan="1" rowspan="1">•  Vaginal/Rectal Swab Specimen Enriched in LimBrotho  Vaginal/Rectal Swab Specimen Enriched inTransVag Broth</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagents/Components</td><td colspan="1" rowspan="1">•  illumigene Control Reagent.  illumigene Reaction Buffer•  illumigene GBS Test Device•  illumigene Heat Treatment Tubes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Amplification</td><td colspan="1" rowspan="1">Self contained and automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Self contained and automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Testing Time</td><td colspan="1" rowspan="1">60 minutes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">illumipro-10'* Automated Isothermal Amplificationand Detection System</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reading Method</td><td colspan="1" rowspan="1">Visible Light Transmission</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Not required</td><td colspan="1" rowspan="1">Same</td></tr><tr><td rowspan="2">Meridian </td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number.</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DEVICEillumigene® GBS                K121044</td><td rowspan=1 colspan=1>PREDICATEillumigene° GBSK112125</td></tr><tr><td rowspan=1 colspan=1>Specimen Types</td><td rowspan=1 colspan=1>Vaginal/Rectal Swab Specimen Enriched in CarrotBroth</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Performance•  Sensitivity•  Specificity</td><td rowspan=1 colspan=1>98.6% [95% CI: 96.5% - 99.5%]93.2% [95% CI: 91.6% - 94.5%]</td><td rowspan=1 colspan=1>97.4% [95% CI: 91.9% - 99.0%]92.3% [95% CI: 90.0% - 94.1%]</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CalanLaboatoy Sanar InstituUs roto orvaluaio QualativT e Approved Guideline- Second Edition (EP12-A)   
Ccal an Laboratoy Stanar nstiue.0.UserVeriationPeorancor recisn anTr Approved Guideline- Second Edition (EP15-A2)   
C ru Second Edition (EP7-A2)

# L. Test Principle:

Th leGro ret ss as o-eitel plati nolog A. LoeiatlfiationAplishe heecall ht rovi and continuous isothermal amplification. Magnesium-pyrophosphate is produced as a by-product of LAMP lsh h ltn panhaplsaneaty eatagesyro u detectable change in sample absorbance and is considered a negative reaction.

# MPerformance Characteristics (if/when applicable):

1. Analytical Performance:

a. Precision/Reproducibility:

Reproucibility studes were completed with Blind code panels  0 samples were upplied nt boatsSmples ny srwih c pe ask amplentihe included contrived samples manufactured as low positive samples (i.e. limit of detection, ${ \mathfrak { n } } = 3$ ) and high negative samples $( n = 3 )$ .The panels also included contrived positive $( n = 3 )$ samples and natural negative samples $( \mathsf { n } = 1 )$ . given in the table below:

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illuigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number.</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 4</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr></table>

b. Linearity/assay reportable range:

Not applicable as this assay is qualitative c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Stability:

Stability studies were completed with K112125 and supplemented for K121044. Sample storage and hold time studies were performed to characterize illumigene® Group B Streptococcus (GBS) assay ranges. Validation studies performed at Meridian indicated that Lim Broth represented the worst-case matrix; therefore studies were completed using Lim Broth.Assay ranges were confirmed for the remaining Transag Broth and Carrot Broth by testing one high negative and one LoD positive sample prepared from each broth.

Stuy results demonstrated that undiluted samples can be held at 19-7 C for up to 6 hours or at 2-8 Cor u o7 days after cultue erihment and prior o testing Samples dilut withilluien® Contro Reagn can be held at 21-7 C for up to 15 minutes prior to heat-treatment. Heat-treated samples may be held at 19-29 C for up to 45 minutes prior to further processing.

Sample freeze/thaw studies were also performed. Samples were enriched 18-24 hours and frozen prior to S we b eh uoa should not be freeze/thawed.

Final testing demonstrated that Lim Broth, in combination with Dacron/polyester, flocked nylon and foam swab types perform acceptably with the illumigene® GS assay.Amies Clear and Calcium Alginate Swabs produced invalid results and are not considered validated for use with illumigene® GBS. Swab types with demonstrated performance in the illumigene® GBS assay appear in the Package Insert.

# d. Detection limit:

Detection limit studies were completed with K112125. Sensitivity studies were designed to determine the lyl limdetengalacn iBro  raigalacte serotypes, were evaluated with the iumigene® GBS assay. Each strain was spiked into negative Lim Broth and diluted serially.A minimum of twenty replicates for each dilution were individually processed and o establish LoTeting was peorme usig three proucon lot  lligen G assay i illumipro-10™ instruments. External Positive and Negative Controls were tested each day throughout the study.

The LoD of the assay ranged from 60 CFU/Test to 1280 CFU/Test. The table below shows the lowes1 concentration for each serotype that produced positive results for 95% of the replicates tested.

<table><tr><td rowspan="2">Meridian </td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td><td rowspan="2"></td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td><td></td></tr></table>

<table><tr><td rowspan=1 colspan=1>· .Serotype</td><td rowspan=1 colspan=1>Streptococcus agalactiae StrainDescription</td><td rowspan=1 colspan=1>. *CFU/Test</td></tr><tr><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>NCTC 11248</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>lb</td><td rowspan=1 colspan=1>ATCC 12401</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>IC</td><td rowspan=1 colspan=1>NCTC 11253</td><td rowspan=1 colspan=1>640</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>11/2</td><td rowspan=1 colspan=1>320</td></tr><tr><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>ATCC 12403</td><td rowspan=1 colspan=1>160</td></tr><tr><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>ATCC BAA-611</td><td rowspan=1 colspan=1>1280</td></tr></table>

Additional S. agalactiae strains were tested and produced positive reactions at 1280 CFU/test with illumigene GBS. Strains and serotypes were tested as follows: Serotype IV: NCTC 11930, hemolytic; Serotype VaNCTC 08188, non-hemolytic; Serotype VII VI/, hemolyic; Serotype VII: VII/, hemoly; Serotype X: NCTC 11249, hemolytic; Unknown Serotype: ATCC 13813, non-hemolytic; and ATCC12386, hemolytic.

Limit of Detection studies are acceptable.

# e. Analytical specificity:

# Interference Testing:

Interference testing was completed with K112125. Selected substances that might be expected to be present in vaginal/rectal swab samples taken from antepartum women were added to a negative Lim broth sample and two contrived positive Lim broth samples. The negative sample was prepared by pooling confirmed negative Lim Broth samples while the contrived positive samples were prepared by spiking a pooled, confirmed negative Lim sample with either Streptococcus agalactiae, strain 11248 Serotype la (123 CFU/test) or Streptococcus agalactiae, strain 12401 Serotype Ib (80 CFU/test). Potentially interfering substances were added to Lim broth samples at final concentrations of $2 . 5 \% v / v$ or greater when the substances could be pipetted. Substances that could not be pipetted were coated onto cotton swabs, imersed in the negative/positive Lim broth samples and testedDilution Controls were prepared by ading a pshate buff sal olution  pla he potentially cross-eactivgans.ac inoula sample was tested in triplicate.

The following substances, at the specified saturated solvent/diluents concentrations, do not interfee with illumigene Group B Streptococcus test results: Amniotic fluid $( 1 0 \% \lor / \lor )$ , Human DNA (100 ng/Test), Urine $( 3 0 \% v / v )$ ,Whole Blood $( 2 . 5 \% \lor / \lor )$ . The following substances do not interfere with test results: Meconium, Stool, Hemorrhoidal cream $\left. 3 0 . 6 5 ~ \mathrm { m g / 1 0 0 m g } \right.$ , Miconazole (fungicide), Mucin $( 0 . 5 - 1 . 5 \% )$ , Spermicidal gel (nonoxynol 9) $\{ 4 ~ \mathrm { m g } / 1 0 0 \mathrm { m g } \}$ . Lubricating gel produced False Negative Results in 1 of 11 replicates tested. Body Powder produced False Negative Results in 1 of 10 replicates tested. Whole Blood at concentrations greater than $2 . 5 \% v / v$ interferes with the illumigene GBS assay.

Interference studies are acceptable.

# Cross-Reactivity Study:

Cross-reactivity studies were completed with K112125. Potentialy cross-reacting microorganisms expected to be present in vaginal/rectal swab specimens were added to negative and contrived positive Lim Broth samples. The negative sample was prepared by pooling confirmed negative Lim Broth samples. The contrived positive sample was prepared by spiking a confirmed negative matrix with Streptococcus agalactie, strain 12401, at 22 CFU/test, near the limit f detection for this strain.Potentially crossreactive microorganisms were added at concentrations of $1 . 2 \times 1 0 ^ { 8 } \thinspace \mathrm { C F U / m L }$ (bacteria and fungi) or virus at a minimum of $1 \times 1 0 ^ { 5 } \tau ( \mathrm { { } L \mathrm { { } } } ) _ { 5 0 } / \mathrm { { m L } }$ (viruses). Dilution controls for each sample were prepared by adding sterile saline solution in place of the potentially cross-reactive microorganisms. Each sample was tested in triplicate. Cross-reactivity with Enterococcus dispar was observed in one of seven replicates tested.

<table><tr><td rowspan="2">Meridian 9</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number.</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

The following microorganisms at the indicated concentrations do not interfere with illumigene GBS: Aeromonas hydrophila, Alcaligenes faecalis, Bacillus cereus, Bacillus subtilis, Bacteroides fragilis, Campylobacter coli, Campylobacter fetus, Campylobacter jejuni, Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Citrobacter freundii, Clostridium bifermentans, Clostridium butyricum, Clostridium difficile, Clostridium histolyticum, Clostridium novyi, Clostridium perfringens, Clostridium septicum, Clostridium sordelli, Clostridium sporogenes, Clostridium tetani, Corynebacterium genitalium, Corynebacterium urealyticum, Corynebacterium xerosis, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus avium, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Escherichia coli 0157:H7, Escherichia fergusonii, Escherichia hermannii, Gardnerella vaginalis, Haemophilus ducreyi, Helicobacter pylori, Klebsiella pneumoniae, Lacluhiu LaccilluLcclu Lacilluubspe Lactobacillus jensenii, Lactococcus lactis, Legionella pneumophila, Listeria monocytogenes, Moraxella osloensis, Morganella morganii, Neisseria gonorrhoeae, Peptostreptococcus anaerobius, Plesiomonas shigelloides, Porphyromonas asaccharolytica, Prevotella melaninogenica, Propionibacterium acnes, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonus fluorescens, Salmonella Group B, Salmonella Group C, Salmonella Group D, Salmonella Group E, Serratia liquefaciens, Serratia marcescens, Shigella boydi, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus aureus (Cowan), Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus anginosus, Streptococcus bovis, Streptococcus dysgalactiae equismilis, Sreptococcus intermedius, Streptococcus mit, Streptococcusralis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sanguinis, Vibrio parahaemolyticus, Yersinia enterocolitica, Adenovirus 40, Adenovirus 41, BK virus, Coxsackievirus, Echovirus, Epstein Barr virus, Herpes Simplex Virus-1, Herpes Simplex Virus-2, Rotavirus.

Mycoplasma genitalium, Mycoplasma hominis and Ureaplasma urealyticum were tested at final concentrations ranging between $1 . 6 \times 1 0 ^ { 6 }$ and $9 . 9 \times 1 0 ^ { 6 } ( \mathsf { F U / m L }$ with no reaction with the illumigene GBS assay.

Cross-reactivity studies are acceptable.

# f. Assay cut-off:

The illumigene Group B Streptococcus Assay has a fixed cut-ff based on the measured change in light transmission at the assay endpoint. Theillumipro-0 measures transmission  light through the Tet nd he Contol ac t he strhe Assay Run Sigalan t he heAsy Ruil. Theilluipr-0calculate that changtranission between he galgalia compa reult o fi cut valuTest results ae eport  Positiver Negative bas on coparione assay cut-off. Fixed cut-off values were based on well characterized clinical specimens.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

Comparison Studies:

a.Method comparison with predicate device: Not applicable   
b. Matrix comparison: Not applicable

Clinical Studies:

a.Clinical Sensitivity:

Cical trials or theilluigene Group BStreptococcus (GBS) assay, including the illumipro-10 Autated Isothermal amplification and detection system, were conducted in 2011 and 2012. Performance characteristics f the illumigene GBS assay were determined by comparison to GBS bacterial culture n two separate studies: (1) Lim and TransVag Broth Enrichment, reference K112125; and (2) Carrot Broth Enrichment. Combined performance data for ll studies and all enrichment broth types is shown in Table 1.

Table 1: illumigene Group B Streptococcus assay performance characteristic   

<table><tr><td rowspan=2 colspan=1>Sample Type</td><td rowspan=1 colspan=3>            Positive Samples        </td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigeneGBS Culture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>285/289</td><td rowspan=1 colspan=1>98.6%</td><td rowspan=1 colspan=1>96.5 - 99.5%</td><td rowspan=1 colspan=1>1045/1121</td><td rowspan=1 colspan=1>93.2%</td><td rowspan=1 colspan=1>91.6 - 94.5%</td></tr><tr><td rowspan=1 colspan=1>Lim Broth</td><td rowspan=1 colspan=1>82/84</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>91.7 - 99.3%</td><td rowspan=1 colspan=1>296/315</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>90.8 - 96.1%</td></tr><tr><td rowspan=1 colspan=1>TransVag Broth</td><td rowspan=1 colspan=1>68/70</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>90.2 - 99.2%</td><td rowspan=1 colspan=1>314/346</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>87.2 -93.4%</td></tr><tr><td rowspan=1 colspan=1>Carrot Broth</td><td rowspan=1 colspan=1>135/135</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.2 - 100.0%</td><td rowspan=1 colspan=1>435/460</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>92.1-96.3%</td></tr></table>

(1) Lim and TransVag Broth Enrichment: illumigene GBS assay performance using Lim Broth and TransVag Broth enriched specimens was evaluated in 2011 by four independent clinical test sites located in the Midwestern and Southern regions of the United States.A total of 826 qualified patient samples were evaluated. Samples were obtained according to established guidelines for the collection of clinical specimens for culture of Group B Streptococcus and enriched for 18-24 hours in either Lim Broth or TransVag Broth prior to illumigene testing. Four hundred three (403, 48.8%) specimens were enriched with Lim Broth and 423 $( 5 1 . 2 \% )$ specimens were enriched with TransVag Broth prior to testing. The age groups of patients tested ranged from 15 years of age to 44 years of age, with age unknown for 3 (0.4%) of the patient population. No differences in test performance were observed based on enrichment medium or patient age. Overall assay Sensitivity was reported as 97.4% [95% Cl: 91.9% - 99.0%] where Specificity was $9 2 . 3 \%$ $9 5 \%$ Cl: $9 0 . 0 \% - 9 4 . 1 \%$ . Table 2 shows assay shows overall assay performance reported for the.study; Table 3 summarizes assay performance by Clinical Site.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

Table 2. Lim and TransVag enrichment performance data   

<table><tr><td rowspan=2 colspan=1>Group B StreptococcusCulture        &quot;&quot;::</td><td rowspan=1 colspan=3>illumigene Group B Streptococcus (GBS)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>-Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>.       4</td><td rowspan=1 colspan=1>154</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>610</td><td rowspan=1 colspan=1>661</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>614</td><td rowspan=1 colspan=1>815</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>150/154</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>.91.9 - 99.0%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>610/661</td><td rowspan=1 colspan=1>92.3%</td><td rowspan=1 colspan=1>90.0 - 94.1%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>760/815</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>91.3 - 94.8%</td></tr></table>

Forty-eight of the 51 false positive results were positive by another molecular method.Invalid results were obtained for 11/826 samples tested or $1 . 3 \%$ . Two of the 11 samples remained invalid after repeat testing of the original sample.

Table 3: Performance characteristics summary; Lim and TransVag Broth Enrichment   

<table><tr><td rowspan=2 colspan=1>Siteidentification</td><td rowspan=2 colspan=1>&quot;Enrichment   Broth</td><td rowspan=1 colspan=3>Positive Samples  :</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>%Sensitivity</td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>%Specificity</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>150/154</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>91.9 - 99.0%</td><td rowspan=1 colspan=1>610/661</td><td rowspan=1 colspan=1>92.3%</td><td rowspan=1 colspan=1>90.0 - 94.1%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>TransVag</td><td rowspan=1 colspan=1>32/33</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>84.7 - 99.5%</td><td rowspan=1 colspan=1>197/199</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>96.4-99.7%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>TransVag</td><td rowspan=1 colspan=1>36/37</td><td rowspan=1 colspan=1>97.3%</td><td rowspan=1 colspan=1>86.2 - 99.5%</td><td rowspan=1 colspan=1>117/147</td><td rowspan=1 colspan=1>79.6%</td><td rowspan=1 colspan=1>72.4 -85.3%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Lim</td><td rowspan=1 colspan=1>38/39</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>86.8 - 99.5%</td><td rowspan=1 colspan=1>162/168</td><td rowspan=1 colspan=1>96.4%</td><td rowspan=1 colspan=1>92.4-98.4%</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>Lim</td><td rowspan=1 colspan=1>44/45</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>88.4 - 99.6%</td><td rowspan=1 colspan=1>134/147</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>85.5 - 94.8%</td></tr></table>

Specimens that generated discrepant results were further evaluated by independent testing laboratories usig FA clearedor laboratory validated molecular assays. Sixteen  nineteen Lim Broth False ositive results were positive by an alternate molecular method. Al thirty-two TransVag Broth False Postive results were positive by an alternate molecular method. In addition to discrepant sample analysis, a selection of concordant samples was tested with non-illumigene molecular methodologies. Concordant result testing showed a combined correlation between molecular methods of $9 7 . 7 \%$ .

() Carrot Broth Enrichment: Performance characteristics specific to Carrot Broth Enrichment were established by studies involving three independent clinical test sites located in the Midwestern and Southern regions of the United States. Independent clinical test sites located in the Midwestern and Southern regions of the United States evaluated a total of 600 qualified patient samples. Samples were obtained according to established guidelines for the collection of clinical specimens for culture of Group B Streptococcus and enriched in Carrot Broth prior to illumigene testing. The age groups of patients tested ranged from 15 years of age to 48 years of age; no differences in test performance were observed based on patient age. Table 4 shows assay performance reported for the study; Table 5 summarizes assay performance by Clinical Site.

<table><tr><td rowspan="2">Meridian </td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

Table 4: illumigene Group B Streptococcus assay performance; Carrot Broth Enrichment   

<table><tr><td rowspan=2 colspan=1>Group B Streptococcus Culture</td><td rowspan=1 colspan=3>illumigene Group B Streptococcus (GBS)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>135</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>460</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>595</td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>135/135</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>97.2 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>435/460</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>92.1 - 96.3%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>570/595</td><td rowspan=1 colspan=1>95.8%</td><td rowspan=1 colspan=1>93.9 - 97.1%</td></tr></table>

Invalid results were obtained for $5 / 6 0 0 ~ ( 0 . 8 \% )$ samples. One of the 5 samples remained invalid after repeat testing.Repeat test results are not included in assay performance calculations. Twenty four of the 25 illumigene Positive: GBS Culture Negative specimens were further analyzed by an independent laboratory developed GBS Molecular Assay. Sixteen of the 24 discrepant samples were positive by the alternate molecular amplification assay.

Table 5: illumigene Group B Streptococcus assay performance by Site   

<table><tr><td rowspan=2 colspan=1>Site  :Identification</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td><td rowspan=1 colspan=2>Invalid Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>%Sensitivity</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>%Specificity</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Invalid/Total</td><td rowspan=1 colspan=1>%Invalid</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135/135</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>97.2 - 100.0%</td><td rowspan=1 colspan=1>435/460</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>92.1 -96.3%</td><td rowspan=1 colspan=1>5/600</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>58/58</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>93.8 - 100.0%</td><td rowspan=1 colspan=1>92/93</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>94.2 - 99.8%</td><td rowspan=1 colspan=1>0/151</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>36/36</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>90.4 - 100.0%</td><td rowspan=1 colspan=1>145/149</td><td rowspan=1 colspan=1>97.3%</td><td rowspan=1 colspan=1>93.3-99.0%</td><td rowspan=1 colspan=1>1/186</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>41/41</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>91.4 - 100.0%</td><td rowspan=1 colspan=1>198/218</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>86.3 -94.0%</td><td rowspan=1 colspan=1>4/263</td><td rowspan=1 colspan=1>1.5%</td></tr></table>

Enriched carrot broth samples were visually inspected or color at the end of the enrichment incubation and prior to initiation of illumigene testing. Table 3 summarizes performance data and observed broth color. Thirty four of the 135 (25.1%) illumigene/GBS Culture positive specimens were reported as showing no visual change in color at the end of enrichment incubation.

Table 6: Performance Characteristics by Carrot Broth Results   

<table><tr><td rowspan=2 colspan=1>Sample Type</td><td rowspan=1 colspan=3>               Positive Samples. &quot;     </td><td rowspan=1 colspan=3>Negative Samples=.</td></tr><tr><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>Sensitivity %**..*</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene/GBS Culture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>Color Change</td><td rowspan=1 colspan=1>100/100</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>96.3 - 100.0%</td><td rowspan=1 colspan=1>2/2</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>34.2 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>No Color Change</td><td rowspan=1 colspan=1>34/34</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>89.8 - 100.0%</td><td rowspan=1 colspan=1>433/458</td><td rowspan=1 colspan=1>94.5%</td><td rowspan=1 colspan=1>92.1 - 96.3%</td></tr><tr><td rowspan=1 colspan=1>Unspecified</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>20.7 - 100.0%</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0 - 0.0%</td></tr></table>

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

. Clinical Specificity: See Section 3a   
C. Other Clinical Supportive Data Not applicable

4Clinical cut-off: Not applicable

5. Expected values/Reference range:

Approximately $10 . 3 0 \%$ of antepartum women are colonized with Group B Streptococcus in the vagina or rectum. Clncal perormance the illigene  Asay was etablishe durig twoclinical studs copletedn 2011 (Lim Broth and TransVag Broth) and 2012 (Carrot Broth). The overall incidence of GBS colonization in antepartum women tested during the 2011 study was $2 4 . 3 \%$ (201 of 826). Incidence of GBS colonization for enrichment performed using Lim Broth was found to be $2 5 . 1 \%$ (101 of 403); while incidence for specimens enriched by TransVag Broth was found to be $2 3 . 6 \%$ (100 of 423). The overall incidence of GBS colonization in antepartum women tested during the 2012 Carrot Broth study was found to be $2 2 . 5 \%$ (135 of 600).

N. Other Supportive Device and Instrument Information:

Instrument:illumipro-10™

# O. System Descriptions:

System Description was reviewed in previous submission, K100818, K110012 and K112125. No systemr software changes were made.

Modes of Operation:

The illumipro- $\mathbf { \nabla } \cdot \mathbf { } \pmb { 1 0 ^ { n } }$ heats each illumigene® GBS Test Device containing prepared samples and Control Reagent, facilitating amplification of target DNA. When S.agalactiae is present in the enriched culture sample, a conserved sequence of the S. agalactiae is amplified and magnesium pyrophosphate is formed. Magnesium pyrophosphate forms a precipitate in the reaction mixture. The illumipro-10 detects the change in light transmission through the reaction mixture created by the precipitating magnesium pyrophosphate. Sample results are reported as Positive or Negative based on the detected change in light transmission.

# 2 Software:

FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:

Yes_ X No_

# 3. Specimen Identification:

The illiruili oftwarutatncubatinndetectionlluieolecularDagos vi diagnostic test reacions. The illumipro-10reports sample results as INVALID POSITIVE or NEGAIVE.

<table><tr><td rowspan="2">Meridian </td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 2:</td><td>510(k) Summary</td></tr></table>

4. Specimen Sampling and Handling:

Specimens are prepared manually. Incubation and detection are automated using the illumipro- ${ \mathfrak { 1 0 } } ^ { m }$ .

5. Calibration:

Calibration of the illumipro- ${ \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot { \bf \nabla } \cdot  \bf$ is not required.

Quality Control:

The illumigene® Group B Streptococus External Control Kit onsists ofa Positie Control Reagent and a Negative Control Reagent.External Control reagents are provided to aid the user in detection of reagent deterioration, adver environmental o test conditions, orvariance n operator performancethat mayedto rsTe Gru  tal Cn  qu ual

Statement for the Record, K 121044   
Meridian BioScience, Inc.   
Illumigene Group B Streptococcus (GBS) DNA Amplification Assay

This $5 1 0 ( \mathbf { k } )$ was reviewed under OIVD's Pilot Triage Program. This program represents an internal workload management tool intended to reduce internal FDA review resources for $5 1 0 ( \mathbf { k } )$ applications that are of good quality upon receipt by FDA.

The information in the 510(k) is complete and supports a substantial equivalence (SE) determination. Please refer to the applicant's 510(k) summary for a summary of the information that supports this SE determination.

Meridian Bioscience, Inc. C/o Michelle L. Smith Senior Director, RA/DA 3471 River Hills Drive Cincinnati, Ohio 45244

Re: k121044 Trade/Device Name: illumigene® Group B Streptococcus (GBS) DNA Amplification Assay Regulation Number: 21 CFR 888.3740 Regulation Name: Streptococcus spp. serological reagents Regulatory Class: Class I Product Code: NJR Dated: April 5, 2012 Received: April 6, 2012

Dear Ms. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffces/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

![](images/aac5d26a0d7e6be5376b7495b4518b27fed9a003eee92a9aeadb95833753edd0.jpg)  
Page 2 - Ms. Michelle L. Smith

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics Device Evaluation and Safety   
Office of Device Evaluation   
Center for Devices and Radiological Health

Enclosure

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Application Number:</td><td>K121044</td></tr><tr><td>Bioscience, Inc.</td><td>Application Section 1:</td><td>Indication(s) for Use Form</td></tr></table>

# Indication(s) for Use Form

510(k) Number: K121044

Device Name: illumigene Group B Streptococcus (GBS) DNA Amplification Assay

# Indications for Use:

the detecion Septo alaci eihe culturetairomvaginalrecta swabspecmesfro broth medium, either Lim Broth, TransVag Broth or Carrot Broth.

monitor treatment for GBS infections.

testing as recommended for penicillin-allergic women.

intended for point-of-care use.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/c3f4cc67e2152823b4282b0ad77bf6b3632d5e86a0f32508cd7482d7668dcdb2.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

5101k) K\$044 (at K121044